DK0941094T3 - Fremgangsmåde til fremstilling af ophthalmiske suspensioner indeholdende brinzolamid - Google Patents

Fremgangsmåde til fremstilling af ophthalmiske suspensioner indeholdende brinzolamid

Info

Publication number
DK0941094T3
DK0941094T3 DK97939835T DK97939835T DK0941094T3 DK 0941094 T3 DK0941094 T3 DK 0941094T3 DK 97939835 T DK97939835 T DK 97939835T DK 97939835 T DK97939835 T DK 97939835T DK 0941094 T3 DK0941094 T3 DK 0941094T3
Authority
DK
Denmark
Prior art keywords
suspensions containing
ophthalmic suspensions
brinzolamide
preparing ophthalmic
containing brinzolamide
Prior art date
Application number
DK97939835T
Other languages
English (en)
Inventor
Robert E Beck
Rex C Sport
Yusuf Ali
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Application granted granted Critical
Publication of DK0941094T3 publication Critical patent/DK0941094T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
DK97939835T 1996-12-11 1997-09-05 Fremgangsmåde til fremstilling af ophthalmiske suspensioner indeholdende brinzolamid DK0941094T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3282096P 1996-12-11 1996-12-11
US08/886,933 US6071904A (en) 1996-12-11 1997-07-02 Process for manufacturing ophthalmic suspensions
PCT/US1997/015727 WO1998025620A1 (en) 1996-12-11 1997-09-05 Process for manufacturing ophthalmic suspensions

Publications (1)

Publication Number Publication Date
DK0941094T3 true DK0941094T3 (da) 2002-01-07

Family

ID=26708929

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97939835T DK0941094T3 (da) 1996-12-11 1997-09-05 Fremgangsmåde til fremstilling af ophthalmiske suspensioner indeholdende brinzolamid

Country Status (14)

Country Link
US (1) US6071904A (da)
EP (1) EP0941094B1 (da)
JP (1) JP3611863B2 (da)
AT (1) ATE209917T1 (da)
CA (1) CA2274680C (da)
DE (2) DE69708912T2 (da)
DK (1) DK0941094T3 (da)
ES (1) ES2169416T3 (da)
FR (1) FR09C0022I2 (da)
HK (1) HK1019704A1 (da)
LU (1) LU91554I2 (da)
NL (1) NL300388I2 (da)
PT (1) PT941094E (da)
WO (1) WO1998025620A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001365A1 (en) * 1998-06-30 2000-01-13 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Prolonged release ophthalmic compositions containing a fluoroquinolone
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
ES2278049T3 (es) 2001-05-21 2007-08-01 Alcon, Inc. Uso de inhibidores de proteasoma para tratar trastornos de ojo seco.
CN1239161C (zh) * 2001-05-21 2006-02-01 爱尔康公司 可用于治疗干眼疾病的类固醇
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
AU2002309963B2 (en) 2001-05-21 2007-03-01 Alcon, Inc. Use of NF-KAPPA-B inhibitors to treat dry eye disorders
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders
ES2283756T3 (es) * 2002-03-01 2007-11-01 Novagali Pharma Sa Sistemas autoemulsionantes de administracion de farmaco para taxoides.
WO2004064828A1 (ja) 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤
ATE497787T1 (de) * 2004-03-12 2011-02-15 Cipla Ltd Sterilisationsprozess für steroide
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
PT1891939E (pt) * 2006-07-28 2013-10-07 Novagali Pharma Sa Composições contendo compostos de amónio quaternário
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
WO2011067791A2 (en) 2009-12-03 2011-06-09 Lupin Limited Process for preparing pharmaceutical ophthalmic compositions
EP2394637A1 (en) * 2010-05-21 2011-12-14 Zaklady Farmaceutyczne Polpharma SA Process for obtaining sterile brinzolamide suspensions
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
ES2708451T3 (es) 2010-07-29 2019-04-09 Allergan Inc Soluciones de bimatoprost y timolol sin conservantes
WO2012053011A2 (en) 2010-10-18 2012-04-26 Usv Limited Ophthalmic compositions comprising brinzolamide
WO2013025696A1 (en) 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Ophthalmic formulations and processes for their preparation
EP2638909A1 (en) 2012-03-15 2013-09-18 Azad Pharmaceutical Ingredients AG Process for preparing sterile Brinzolamide
GR1007906B (el) 2012-03-22 2013-05-30 Φαρματεν Αβεε, Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου
KR101966830B1 (ko) * 2012-05-09 2019-04-08 아이크롬 에스피에이 무균 활성 약제 성분의 제조 방법
US20150119386A1 (en) * 2012-05-21 2015-04-30 Aurobindo Pharma Limited Process for preparing opthalmic suspension of brinzolamide
EP2906198B1 (en) 2012-10-11 2019-04-03 Indoco Remedies Limited A process for manufacturing sterile brinzolamide ophthalmic suspension
CN104721136A (zh) * 2013-02-21 2015-06-24 四川大学 一种布佐林胺眼用纳米混悬剂及其制备方法
UA116273C2 (uk) * 2013-10-17 2018-02-26 Сентісс Фарма Прайвет Лімітед Офтальмологічний фармацевтичний склад, що не містить консерванта
US9820991B2 (en) * 2013-11-08 2017-11-21 Sentiss Pharma Private Limited Pharmaceutical composition comprising brinzolamide
US10463674B2 (en) 2013-11-08 2019-11-05 Sentiss Pharma Private Limited Process for manufacturing sterile ophthalmic pharmaceutical suspensions
ES2838756T3 (es) * 2014-01-24 2021-07-02 Sentiss Pharma Private Ltd Composición farmacéutica que comprende brinzolamida
PL407710A1 (pl) 2014-03-28 2015-10-12 Instytut Farmaceutyczny Sposób wytwarzania preparatu kropli do oczu w postaci zawiesiny zawierającej brynzolamid i preparat wytworzony tym sposobem
JP6279395B2 (ja) * 2014-05-01 2018-02-14 東亜薬品株式会社 ブリンゾラミド懸濁性点眼液組成物の製造方法
WO2016063184A1 (en) 2014-10-20 2016-04-28 Sentiss Pharma Private Limited Ophthalmic solution
TWI664965B (zh) 2015-06-22 2019-07-11 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
CN107582519A (zh) * 2017-06-01 2018-01-16 合肥远志医药科技开发有限公司 一种布林佐胺滴眼液制剂及其制备方法
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
JP2021521240A (ja) 2018-04-25 2021-08-26 シルパ メディケア リミテッドＳｈｉｌｐａ Ｍｅｄｉｃａｒｅ Ｌｉｍｉｔｅｄ ブリンゾラミドの眼科用組成物
GR1009616B (el) * 2018-07-20 2019-10-11 Φαρματεν Α.Β.Ε.Ε. Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει βρινζολαμιδη και τιμολολη και μεθοδος παρασκευης αυτου
WO2020240451A1 (en) 2019-05-29 2020-12-03 Lupin Limited In-situ gelling nanoemulsion of brinzolamide
US11850249B2 (en) 2020-10-05 2023-12-26 Somerset Therapeutics, Llc Methods of efficiently reducing intraocular pressure

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
WO1992018124A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. OPHTHALMIC COMPOSITIONS COMPRISING COMBINATIONS OF A CARBONIC ANHYDRASE INHIBITOR AND A β-ADRENERGIC ANTAGONIST
ATE169499T1 (de) * 1992-02-21 1998-08-15 Alcon Lab Inc Topische antiglaukoma zusammensetzungen, enthaltend karbonhydrasehemmer und beta-blocker
US5362758A (en) * 1992-09-18 1994-11-08 Pfizer Inc. Ophthalmic piroxicam solution
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system

Also Published As

Publication number Publication date
PT941094E (pt) 2002-05-31
DE122009000016I1 (de) 2009-06-25
ATE209917T1 (de) 2001-12-15
US6071904A (en) 2000-06-06
CA2274680A1 (en) 1998-06-18
ES2169416T3 (es) 2002-07-01
JP2000501749A (ja) 2000-02-15
FR09C0022I2 (da) 2010-06-11
NL300388I1 (nl) 2009-07-01
NL300388I2 (nl) 2010-02-01
AU718079B2 (en) 2000-04-06
AU4183897A (en) 1998-07-03
EP0941094B1 (en) 2001-12-05
JP3611863B2 (ja) 2005-01-19
EP0941094A1 (en) 1999-09-15
DE69708912T2 (de) 2002-04-11
FR09C0022I1 (da) 2009-09-25
LU91554I2 (fr) 2009-06-22
CA2274680C (en) 2003-11-18
HK1019704A1 (en) 2000-02-25
DE69708912D1 (de) 2002-01-17
WO1998025620A1 (en) 1998-06-18

Similar Documents

Publication Publication Date Title
DK0941094T3 (da) Fremgangsmåde til fremstilling af ophthalmiske suspensioner indeholdende brinzolamid
DK0552321T3 (da) Fremgangsmåde til fremstilling af påtegninger på diamanter
NO953282D0 (no) Fremgangsmåte for bedring av produktiviteten til en brönn
DE68918327T3 (de) Programmierungsschnittstelle für Hörgeräte.
DE69009991D1 (de) Leistungsstarkes wirkungsvolles hörhilfegerät.
MX9606203A (es) Derivados heterociclicos sustituidos.
NO944464D0 (no) Framgangsmåte for sikker kommunikasjon
YU15599A (sh) Intermedijari i proces za dobijanje olanzapina
NO904955L (no) Fremgangsmaate for fremstilling av acat-inhibitorer.
NO894583D0 (no) Fremgangsmaate for fremstilling av celleplast.
PT1027315E (pt) Processo para a producao de n-butanol.
NO904801D0 (no) Fremgangsmaate for fremstilling av acat-inhibitorer.
AU8467398A (en) Fluorescent photosensitive glasses and process for the production thereof
DK0712263T3 (da) Programmerbart høreapparat.
DK0748237T3 (da) Middel til fremstilling af en aerosol
FR2714272B3 (fr) Porte-monnaie annulaire.
DE69504170D1 (de) Laserherstellungsverfahren
DE68913672D1 (de) N-substituierte Maleimid-Herstellungsverfahren.
DE69111019D1 (de) Entparaffinierungsprozess.
DK0788587T3 (da) Fremgangsmåde til fremstillling af ledskiver
FI903088A0 (fi) Process foer framstaellning av straengsprutade skumkroppar.
DE69109307D1 (de) Hörgerät.
NO910894D0 (no) Fremgangsmaate til fremstilling av cefalosporin.
AU9629098A (en) Ophthalmic lens production process
NO912520L (no) Fremgangsmaate for fremstilling av hydrokarboner, samt apparat for anvendelse av fremgangsmaaten.